Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Gastric CancerOrganoidNeoadjuvant Therapy
Interventions
DRUG

Oxaliplatin

"According to the first-line drugs provided by the NCCN guidelines, the concentration of each drug was added to the organoid culture medium after setting 5-6 concentration gradients according to literature reports. Chemo-sensitive and drug-resistant.~Construction of gastric cancer organoid T cell co-culture system to screen sensitive immunotherapy drugs."

Trial Locations (1)

100021

RECRUITING

Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/ National Clinical Research for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Dong Bing Zhao

OTHER